Jersey reinvented itself. A forty-five square mile island once known for offshore finance is now exporting pharmaceutical-grade cannabis into Germany’s booming medical market. With strict regulation, heavy investment, and a government eager for diversification, Jersey has become an unlikely European powerhouse. The contradiction between local policing and global commerce tells the real story.
MS LIMITS MEDICAL CANNABIS WHERE IT MATTERS MOST
Mississippi maintains strict limits on medical cannabis after Governor Tate Reeves vetoed expansion bills on March 26, 2026. Patients remain unable to use cannabis in hospitals while eligibility and access rules stay tightly controlled. This feature examines what the veto blocks, how it affects patients, and what it means for the state’s growing cannabis market.
Zoned for Hypocrisy
A new medical cannabis dispensary on South Carrollton Avenue in New Orleans is labeled "controversial" in a corridor already saturated with alcohol and tobacco sales. This piece examines how zoning laws, stigma, and selective moral outrage continue to frame cannabis as a threat while more harmful substances remain normalized.
The South’s Quiet Cannabis Rebellion
Across Mississippi, Louisiana, and Alabama, quiet legalization is replacing old fear. Dispensaries open, hemp farms thrive, and police turn away from small possession. Lawmakers who once preached prohibition now profit from regulation. The Bible Belt’s cannabis rebellion is alive and growing, and the South is no longer waiting for Washington to catch up.
The Corporate Cure for Cannabis
A German biotech is pushing a cannabis pill called VER 01 and calling it a breakthrough for pain relief. Beneath the pharmaceutical polish is a deeper story about control, money, and culture. Pot Culture Magazine asks if Vertanical’s lab born weed is progress or just another corporate grab for the plant the people built.
All Talk, No Toke for Veterans
The VA finally let doctors talk to veterans about cannabis, but they still can’t prescribe it. After decades of silence, this small policy shift feels too little and too late. Our feature exposes how bureaucratic cowardice and federal hypocrisy keep veterans from accessing the medicine they fought for.